20/20 BioLabs Announces Launch And Commercial Availability Of OneTest For Longevity Solution, Built With IBM AI Capabilities
Benzinga Newsdesk 8 months ago
News
Recently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers, Dietary Habits, and Curated Scientific Research to Deliver Personalized Health InsightsGAITHERSBURG, Md., Feb. 25, 2026
Recently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers, Dietary Habits, and Curated Scientific Research to Deliver Personalized Health Insights
GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs (NASDAQ:AIDX), an early market leader in cutting-edge, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announces the launch and commercial availability of its OneTest for Longevity solution. The solution uses IBM watsonx.ai – an integrated AI application development studio – to analyze data, to help individuals track chronic inflammation associated with several major chronic diseases. The test is now available for purchase.
The OneTest for Longevity solution uses IBM watsonx.ai* to calculate and display an individual's risk of being diagnosed with chronic diseases such as diabetes, dementia, and cardiovascular disease. The product provides personalized, evidence-based dietary recommendations to help individuals better understand patterns in their biomarker levels and associated disease risks.